Abstract

Efficacy of Biologics in Early vs. Established Rheumatoid Arthritis

Author(s): Noor Fatima Fadi*

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive joint damage. The introduction of biologic therapies has significantly changed the management of RA, offering targeted treatments that can alter disease progression. This article reviews the efficacy of biologics in early versus established RA, highlighting clinical evidence, treatment outcomes, and the implications of timing in therapy. Early intervention with biologics is associated with improved remission rates, reduced joint damage, and enhanced quality of life compared to treatment initiated in established RA. Although biologics remain effective in more advanced stages, the variability in patient responses underscores the importance of early diagnosis and intervention. Challenges such as accessibility, cost, and long-term safety continue to impact treatment outcomes. Future directions include personalized medicine approaches and novel biologics aimed at optimizing treatment strategies for all RA patients.